Volpara Health Technologies (ASX:VHT) chief executive and co-founder Dr. Ralph Highnam explains to Proactive Investors the research, development, and manufacturing company's clinically-validated imaging analytics and analysis software. Volpara specialises in products that improve clinical decision-making and the early detection of breast cancer, boasting both US Food and Drug Administration (FDA) and Conformité Européenne (CE) mark approval.
The company is driving growth by pushing international sales, particularly in the USA, and by developing new capabilities, including some AI, that will push up revenue per patient. A $20 million raise to fund expansion plans has recently been completed. Volpara has set an annual recurring revenue goal of $9 million for this year.